Abstract
To explore the relationship between NF2 promoter gene mutation and the risk of medulloblastomas (MBs). We collected tissues from 16 MB patients and 7 age-matched non-MB controls. Gene sequencing, qPCR (real-time quantitative polymerase chain reaction), IHC (immunohistochemistry), and WB (Western blot) were used to analyze the changes in the NF2 gene sequence and expression between patients and controls. We found that NF2 promoter gene mutations occurred in MB patients. The NF2 mRNA expression was higher in the controls than in patients (p = 0.03 < 0.05); however, the results of IHC and WB demonstrated that the NF2 protein expression was significantly higher in patients than in the controls (IHC: p = 0.0001; WB: p = 0.01). There was no significant difference in the CRL4 mRNA and protein levels. In addition, NF2 protein was mainly expressed in the nucleus in MB patients, while the NF2 protein was mainly expressed in the cytoplasm in the controls. NF2 promoter mutations exist in MB patients. NF2 mRNA expression was higher in controls than patients; whereas NF2 protein level was higher in patients than in controls.
Similar content being viewed by others
References
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1
Macdonald TJ, Aguilera D, Castellino RC (2014) The rationale for targeted therapies in medulloblastoma. Neuro-Oncology 16(1):9–20
Omuro A, Deangelis LM (2013) Glioblastoma and other malignant gliomas. J Am Med Assoc 310(17):1842–1850
Giangaspero F, Wellek S, Masuoka J, Gessi M, Kleihues P, Ohgaki H (2006) Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol 112(112):5–12
Mueller S, Chang S (2009) Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics 6(3):570–586
Gupta T, Jalali R, Goswami S, Nair V, Moiyadi A, Epari S, Sarin R (2012) Early clinical outcomes demonstrate preserved cognitive function in children with average-risk medulloblastoma when treated with hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys 83(5):1534–1540
Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, Carter JJ, Wurscher M, Johnson LG, Galloway DA, Daling JR (2007) Risk of cervical cancer associated with chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 120(3):650–655. https://doi.org/10.1002/ijc.22325
Zanini C, Baci D, Mandili G, Leone M, Morra I, Forni M (2010) Proteomic profile modification of anaplastic medulloblastoma after in-vivo radiotherapy: a case study. J Cancer Ther 01(2):97–103
Beltrami S, Kim R, Gordon J (2013) Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator. Anticancer Res 33(1):1–11
Mo JS, Park HW, Guan KL (2014) The hippo signaling pathway in stem cell biology and cancer. EMBO Rep 15(6):642–656
Visser S, Yang X (2009) Identification of LATS transcriptional targets in HeLa cells using whole human genome oligonucleotide microarray. Gene 449(1–2):22–29
Yang W, Dong Q, Zhang Q, Li Z, Wang E, Qiu X (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101(5):1279–1285
Harvey K, Tapon N (2007) The Salvador-warts-hippo pathway—an emerging tumour-suppressor network. Nat Rev Cancer 7(3):182–191
Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D (2013) Spatial organization of hippo signaling at the plasma membrane mediated by the tumor suppressor merlin/NF2. Cell 154(6):1342–1355
Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P (2001) The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15(8):968–980
Ongaratti BR, Silva CB, Trott G, Haag T, Leães CG, Ferreira NP, Oliveira MC, Pereiralima JF (2016) Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence. Braz J Med Biol Res = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica [et al] 49 (4)
Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29(12):841–846
Bikhazi PH, Kim EJ, Attaie A, Bikhazi NB, Lalwani AK (1998) Germline screening of the NF-2 gene in families with unilateral vestibular schwannoma. Otolaryngol Head Neck Surg 117(2):1–6
Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, Maccollin M (2003) Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 40(2):109–114
Mérel P, Hoang-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, Moisan JP, Resche F, Nishisho I, Estivill X (1995) Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 13(3):211–216
Lan K, Mautner VF (1996) A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet 97(2):224–227
Fernandezl A, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD, Kenney AM (2009) YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates sonic hedgehog-driven neural precursor proliferation. Genes Dev 23(23):2729–2741
Okada T, Fg LLM (2005) Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 171(2):361–371
Reifenberger J, Wolter M, Weber R, Megahed M, Ruzicka T, Lichter P, Reifenberger G (1998) Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 58(9):1798–1803
Fernandez-L A, Squatrito M, Northcott P, Awan A, Holland EC, Taylor MD, Nahlé Z, Kenney AM (2012) Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene 31(15):1923–1937
Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB (2010) Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140(4):477–490
Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, Meadows AT, Friedman D, Robison LL, Diller L (2004) Breast cancer after childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med 141(8):590–597
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai Z-C, Guan K-L (2007) Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21(21):2747–2761
Deng L, Ma C, Yuan Q, Gao X, Yang C (2005) Total RNA extracted from brain tissue of rat by trizol reagent. J Luzhou Med College 28(6):505–506
Yang CS, Liang XL, Jian-Ying LI, Yan ZW, Huang F (2005) Effect of the mutation of promoter region in Wilson disease ATP7B gene on the expression of reporter gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22(5):566–568
Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4(4):405–415
Chen CH, Cao YL, Hu WC (2007) Apolipoprotein C-II promoter T→A substitution at position −190 affects on the transcription of the gene and its relationship to hyperlipemia. Biochem Biophys Res Commun 354(1):62–65
Kendrick N (2014) A gene's mRNA level does not usually predict its protein level. Kendrick Laboratories, Inc, 1202 Ann St, Madison, WI 53713
Schulze KMM, Hanemann CO, Müller HW, Hanenberg H (2002) Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 11(1):69–76
Yi C, Troutman S, Fera D, Stemmerrachamimov A, Avila JL, Christian N, Persson NL, Shimono A, Speicher DW, Marmorstein R (2011) A tight junction-associated Merlin-angiomotin complex mediates Merlin’s regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 19(4):527–540
Ongaratti BR, Silva CB, Trott G, Haag T, Leães CG, Ferreira NP, Oliveira MC, Pereiralima JF (2016) Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence. Braz J Med Biol Res 49(4):e5125
Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q (2008) Merlin is a potent inhibitor of glioma growth. Cancer Res 68(14):5733–5742
Morrow KA, Das S, Meng E, Menezes ME, Bailey SK, Metge BJ, Buchsbaum DJ, Samant RS, Shevde LA (2016) Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. Oncotarget 7(14):17991–18005
Benhamouche S, Curto MI, Gladden AB, Liu CH, Giovannini M, Mcclatchey AI (2010) Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 24(16):1718–1730
Horiguchi A, Zheng R, Shen R, Nanus DM (2008) Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate 68(9):975–984
Zhao Z, Lu T, Zhang N, Wang Y, He X, Zhang B, Huang J (2015) Study on the expression of neurofibromatosis 2 gene and its dinieal significance in primary liver cancer. Int J Clin Exp Med 7:535–538
Chou TT, Trojanowski JQ, Lee VM (1997) Neurotrophin signal transduction in medulloblastoma. J Neurosci Res 49(5):522–527
Eberhart C, Tihan T, Burger PC (2000) Nuclear Localization and Mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 59:333–337. https://doi.org/10.1093/jnen/59.4.333
Bianchi AB, Testa JR (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 92(24):10854–10858
Funding
No funding was received for this research.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants or their guardians included in the study.
Rights and permissions
About this article
Cite this article
Zhao, C., Chen, Q., Li, C. et al. The association of NF2 (neurofibromin 2) gene polymorphism and the risk of medulloblastomas. Neurol Sci 39, 1175–1183 (2018). https://doi.org/10.1007/s10072-018-3327-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-018-3327-0